Introduction
============

Alzheimer's disease (AD), the most common form of dementia, is a neurodegenerative disorder that adversely affects memory, comprehension, judgment, thinking, orientation, language, and calculation. Alzheimer's disease places a considerable progressive burden on the principal caregiver ([@b31-ndt-2-121]). The number of people with AD in the USA is 4 million and is predicted to more than treble by 2050 ([@b33-ndt-2-121]). [@b19-ndt-2-121] estimated that AD comprises more than 50% of total dementia cases. The economic impact of this illness is enormous, exceeding US\$100 billion annually in the USA ([@b6-ndt-2-121]).

In AD, degeneration of basal forebrain cholinergic pathways linked with the cortex is thought to cause the cognitive deficiencies ([@b4-ndt-2-121]). Two pharmacological treatments are available: memantine and the cholinesterase inhibitors (ChEI). These affect different neurotransmitter systems. ChEIs block enzymes that metabolise acetylcholine and therefore increase its levels ([@b5-ndt-2-121]). Donepezil, galantamine, and rivastigmine inhibit acetyl cholinesterase ([@b20-ndt-2-121]). Inhibition of both butyrylcholinesterase and acetyl cholinesterase for rivastigmine ([@b16-ndt-2-121]), and nicotinic modulation for galantamine ([@b29-ndt-2-121]) may contribute to the efficacy of these ChEIs.

The overactivation of glutamate, particularly N-methyl-D-aspartate (NMDA)-selective receptors, has been associated with the degeneration of cholinergic function seen in AD ([@b13-ndt-2-121]). Memantine may prevent glutamate-induced neuronal damage by noncompetitive antagonism of the NMDA receptor ([@b17-ndt-2-121]).

Current treatments may lack a clinically significant effect and new treatment strategies are essential to assist in disease management ([@b1-ndt-2-121]; NICE 2005). Combining memantine's potential neuroprotective effect with the improvement in cholinergic functioning noted with a ChEI may lead to additional therapeutic benefits ([@b36-ndt-2-121]). Recent animal studies have indicated a ceiling effect on benefit in memory impairment and additive or synergistic effects of combining memantine with a ChEI ([@b37-ndt-2-121]), which is the basic science rationale. We set out to review the research evidence on combination.

Method
======

A computerized literature search of Medline (1966--July 2005), PsycINFO (1972--September 2005), Embase (1980--July 2005), Cinhal (1982--September 2005) and the Cochrane Collaboration was conducted. Keywords used were: AD, randomized controlled trials (clinical trial, single-blind method, double-blind method, random allocation), open-label studies, cholinesterase inhibitors (donepezil, rivastigmine, galantamine, galanthamine, and tacrine), and memantine. The reference section of studies identified was scrutinized, the relevant pharmaceutical manufacturers were contacted for any unpublished studies, and the US trials database (<http://www.clinicalstudyresults.org/search/>) was examined. Single cases and non-AD studies were excluded.

Results
=======

In total, five studies were identified. One trial is published only in summary format online ([@b11-ndt-2-121]) and in a poster meta-analysis ([@b9-ndt-2-121]). This poster, however, contains only limited data ([@b9-ndt-2-121]), and Forest Laboratories were unable to provide more detailed information (Forest Laboratories Inc 2005 July 7, pers comm). One study was published in a peer-reviewed journal ([@b34-ndt-2-121]). Three similar prospective studies have been published only in abstract format ([@b25-ndt-2-121]; [@b26-ndt-2-121]; [@b32-ndt-2-121]).

Trial design
============

Two studies were multicenter, randomized, double-blind, placebo-controlled ([@b11-ndt-2-121]; [@b34-ndt-2-121]; [@b9-ndt-2-121]), and three studies were open label ([@b25-ndt-2-121]; [@b26-ndt-2-121]; [@b32-ndt-2-121]). The randomized, controlled trials (RCTs) ([@b11-ndt-2-121]; [@b34-ndt-2-121]; [@b9-ndt-2-121]) were not designed to determine the relative efficacy compared with placebo of memantine monotherapy, donepezil monotherapy, or combination therapy, but whether memantine would provide additional benefit in a patient already on a ChEI.

Study duration varied from 24 to 26 weeks. [@b34-ndt-2-121] randomized 203 patients to memantine and 201 to placebo. The sample sizes of the open studies varied from 12 to 25 ([@b25-ndt-2-121]; [@b26-ndt-2-121]; [@b32-ndt-2-121]). Patient numbers were not available for one study ([@b11-ndt-2-121]) except in a poster meta-analysis (n = 433) ([@b9-ndt-2-121]).

[@b11-ndt-2-121] maintained patients on a stable dose for a ChEI (exact details not stated) for at least 6 months prior to entry. [@b34-ndt-2-121] maintained patients on donepezil for at least 6 months, and at a stable dose of 5--10 mg daily for at least 3 months prior to the study. None of the open studies stated how long patients had been taking a ChEI before memantine was begun ([@b25-ndt-2-121]; [@b26-ndt-2-121]; [@b32-ndt-2-121]).

Diagnostic criteria were: National Institute of Neurological and Communicative Disorders and Stroke--Alzheimer Disease and Related Disorders Association (NINCDS--ARDA) diagnosis of probable AD ([@b11-ndt-2-121]; [@b34-ndt-2-121]; [@b9-ndt-2-121]); DSM-IV ([@b2-ndt-2-121]); and NINCDS--ARDA for possible Alzheimer's disease ([@b25-ndt-2-121]; [@b26-ndt-2-121]; [@b32-ndt-2-121]). Disease stage ranged from mild to moderate AD in one RCT ([@b11-ndt-2-121]; [@b9-ndt-2-121]) to moderate to severe AD in the other ([@b34-ndt-2-121]). The three open studies did not specify the stage ([@b25-ndt-2-121]; [@b26-ndt-2-121]; [@b32-ndt-2-121]).

Assessment measures
===================

[@b34-ndt-2-121] assessed efficacy with the Severe Impairment Battery (SIB) ([@b24-ndt-2-121]), a modified 19-item AD Cooperative Study--Activities of Daily Living Inventory (ADCS--ADL19) ([@b15-ndt-2-121]), the Clinician's Interview-Based Impression of Change Plus Caregiver Input (CIBIC-Plus) ([@b30-ndt-2-121]), the Neuropsychiatric Inventory (NPI) ([@b8-ndt-2-121]), and the Behavioral Rating Scale for Geriatric Patients (BGP) ([@b35-ndt-2-121]). [@b11-ndt-2-121] assessed global outcomes (CIBIC-Plus) and Alzheimer's Disease Assessment Scale cognitive outcomes (ADAS-Cog); secondary outcomes were the NPI and the ADCS--ADL23 ([@b9-ndt-2-121]). Three studies assessed memory objectively (exact scale not stated) and used caregiver report to assess effect on cognition and functioning ([@b25-ndt-2-121]; [@b26-ndt-2-121]; [@b32-ndt-2-121]). None of the studies utilised outcome instruments such as time to residential admission or death.

Caregivers rated tolerability and adverse events in three studies ([@b25-ndt-2-121]; [@b26-ndt-2-121]; [@b32-ndt-2-121]). One study assessed emergent adverse events by patient report and vital sign, physical examination, laboratory, and electrocardiogram testing ([@b34-ndt-2-121]). [@b11-ndt-2-121] reported adverse events in a pooled analysis of six trials ([@b9-ndt-2-121]).

Efficacy
========

[@b34-ndt-2-121] reported that at week 24 using last observation carried forward (LOCF) and observed cases (OC), memantine with donepezil produced a statistically significant improvement in the SIB, ADCS--ADL, CIBIC-Plus, NPI, and BGP in patients with moderate to severe AD compared with donepezil and placebo (see [Table 1](#t1-ndt-2-121){ref-type="table"} for full details).

It may be difficult to relate results from psychometric scales to a clinical setting ([@b14-ndt-2-121]; [@b1-ndt-2-121]) and the clinical significance of combination therapy is unclear. The effect size of 0.36 on cognition, although small ([@b7-ndt-2-121]), is of comparable magnitude to that of the ChEIs ([@b28-ndt-2-121]). The effect size for function at 0.12 is very small and raises the issue of clinical relevance. The relative improvements were limited when the full range of each scale is considered, making it impossible to assess response rates, and data were not made available despite requests. Floor effects may have influenced the NPI and BGP results, as the baseline readings indicated only mild impairment.

A second trial failed to demonstrate that combination therapy is significantly more effective than ChEI monotherapy in patients with mild to moderate AD ([@b11-ndt-2-121]; [@b9-ndt-2-121]). Combination therapy did not produce a statistically significant difference on global or cognitive outcomes compared with placebo--ChEI. Over 24 weeks there was no change in cognition in the memantine--ChEI group and the decline in cognition in the placebo--ChEI group was less than expected. The small group difference was not statistically significant (exact p value not stated).

The three open studies noted improvements in carer-rated cognition, but failed to demonstrate objective memory improvements ([@b25-ndt-2-121]; [@b26-ndt-2-121]; [@b32-ndt-2-121]). Furthermore any effect noted in the open studies should be treated cautiously because of the potential for false positive outcomes owing to random variability, placebo effects, and bias ([@b18-ndt-2-121]).

Adverse events
==============

Significantly more patients on memantine--donepezil compared with placebo--donepezil completed one study (85.1% \[n = 172\] vs 74.6% \[n = 150\], p = 0.01) ([@b34-ndt-2-121]), suggesting that the combination was not associated with significantly greater side effect burden than the ChEI alone. Adverse events that occurred twice as frequently with memantine were: confusion (7.9% vs 2.0%; p = 0.01), and headache (6.4% vs 2.5%; p = 0.09) ([@b34-ndt-2-121]). Adverse events occurred in 78% of patients on memantine, and 72% of patients on placebo (p not stated) ([@b34-ndt-2-121]). This high rate of adverse events may provide an accurate reflection of adverse events in the wider population of nonstudy patients. Future trials should take into account the fact that the patient selection criteria of placebo-controlled studies may overestimate the incidence of adverse events associated with placebo ([@b3-ndt-2-121]) owing to the nature of the underlying disorder.

One study has not mentioned tolerability to date except as a pooled figure, which makes specific commentary impossible ([@b11-ndt-2-121]; [@b9-ndt-2-121]). Discontinuation rates of 7.9% with placebo and 6% with memantine may indicate that memantine lacks efficacy in the milder stages of AD ([@b9-ndt-2-121]). No patients discontinued treatment or reported adverse events in the open studies ([@b25-ndt-2-121]; [@b26-ndt-2-121]; [@b32-ndt-2-121]).

Conclusion
==========

On the current available evidence, the use of memantine--ChEI combination therapy cannot be recommended as there is no evidence that combination therapy is more effective than memantine monotherapy ([@b34-ndt-2-121]). On common outcome measures, [@b27-ndt-2-121] demonstrated a larger memantine monotherapy--placebo signal than the memantine--donepezil combination/placebo--donepezil signal ([@b34-ndt-2-121]). The negative mild AD study (FPI 2003; [@b9-ndt-2-121]) in our opinion backs the US Food and Drug Administration decision not to allow license extension to mild AD ([@b12-ndt-2-121]).

The difficulty in obtaining full access to relevant studies is of concern and makes developing evidence-based recommendations problematic. Clinicians should have full access studies as directed by new US legislation (<http://www.clinicalstudyresults.org/search/>). The publication of a meta-analysis that includes dementia at various stages in advance of full publication or full data disclosure may obscure negative results ([@b21-ndt-2-121]; [@b9-ndt-2-121]).

Healthcare provider guidelines need to consider the economic impact of combination prescribing in a situation where the cost benefits of cognitive is already controversial (NICE 2005; [@b22-ndt-2-121]).

No adequate study has yet been presented to determine whether ChEI combined with memantine has a synergistic effect. Further studies including three arms: memantine--placebo, placebo--ChEI, and memantine--ChEI, are required to develop the evidence base. Studies should concentrate on patients with moderate to severe AD and include a 12-month extension arm to determine if efficacy is sustained. Active treatments should be assessed for a clinical effect in addition to a statistically significant effect. Future studies should evaluate the efficacy of combination therapy in non-AD dementia and include formal economic evaluations and pragmatic efficacy assessments such as time to residential facility.

Key points
==========

On the current dataset the use of memantine--ChEI combination therapy cannot be endorsed.

Future studies should include three arms: memantine--placebo, placebo--ChEI, and memantine--ChEI.

Before adding in memantine, ChEIs should be discontinued or, once on therapeutic dose of memantine, be discontinued in a tapered manner with regular review.

Clinicians should be granted full access to the data at the earliest opportunity.
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###### 

Efficacy outcomes (least squares mean score \[SE\]) baseline to week 24 change -- memantine--donepezil vs placebo--donepezil ([@b34-ndt-2-121])

  Rating scale                   LOCF                                     Observed cases
  ------------------------------ ---------------------------------------- ----------------------------------------
  SIB                            0.9 (0.67) vs −2.5 (0.69); p \< 0.001    1.0 (0.70) vs −2.4 (0.74); p \< 0.001
  ADCS--ADL                      −2.0 (0.50) vs −3.4 (0.51); p = 0.03     −1.7 (0.51) vs −3.3 (0.55); p = 0.02
  CIBIC--Plus                    4.41 (0.074) vs 4.66 (0.075); p = 0.03   4.38 (0.081) vs 4.64 (0.087); p = 0.03
  NPI                            −0.1 (0.98) vs 3.7 (0.99); p = 0.002     −0.5 (0.99) vs 2.9 (1.06); p = 0.01
  BGP dependency care subscale   0.8 (0.37) vs 2.3 (0.38); p = 0.001      0.6 (0.37) vs 2.2 (0.40); p = 0.001

**Abbreviations:** ADCS--ADL, Alzheimer's disease Cooperative Study--Activities of Daily Living Inventory ([@b15-ndt-2-121]); BGP, Behavioral Rating Scale for Geriatric Patients ([@b35-ndt-2-121]); CIBIC-Plus, Clinician's Interview-Based Impression of Change Plus Caregiver Input ([@b30-ndt-2-121]); LOCF, last observation carried forward; NPI, Neuropsychiatric Inventory ([@b8-ndt-2-121]); SIB, Severe Impairment Battery ([@b24-ndt-2-121]).
